Carbon dioxide embolism during transanal total mesorectal excision (taTME)
Transanal total mesorectal excision (taTME) is a relatively new surgical approach that has become increasingly common for patients with low rectal cancer. This approach uses subperitoneal carbon dioxide (CO2) to create the pelvic workspace and perform the operation from the anal side. Thereby, a good surgical performance is achieved for a narrow pelvis, which is difficult with laparoscopy from the abdominal side. However, taTME is associated with potentially life-threatening complications, including CO2 embolism , which is not a commonly encountered complication during laparoscopic TME. This complication may be important in a transanal approach, and surgeons performing taTME need to be aware of this potential event to prevent major morbidity. Here, we report our experience with 2 patients who had a sudden drop in end-tidal carbon dioxide (ETCO2) that was suspected to be due to CO2 embolism during taTME.
The patient was a 54-year-old man with low...
All authors declare that they contributed to this article and approved the final submitted version. TS and YN collected data, wrote the manuscript, and contributed equally to the manuscript.
Departmental support only.
Compliance with ethical standards
Conflict of interest
Dr. Ito is on the speakers’ bureaus of Johnson & Johnson K.K., Eisai Co., Ltd., Olympus Corporation, Medtronic plc, Chugai Pharmaceutical Co., Ltd., KAKEN PHARMACE, UTICAL CO., LTD., Stryker Japan K.K., Covidien Japan, TAIHO PHARMACEUTICAL CO., LTD., Yakult Honsha Co., Ltd., Fujita Medical Instruments Co., Ltd., Japan Medical Engineering Institute, MSD K.K., Merck Serono Co., Ltd., Medical Leaders Co., Ltd., Takeda Pharmaceutical Company Limited, Applied Medical, MC Medical, Inc., EA Pharma Co., Ltd., and ConMed Japan KK. He received Grants of ConMed Japan KK, Mitsubishi Precision, MURANAKA MEDICAL INSTRUMENTS, FUJITA MEDICAL INSTRUMENTS, and A1 Technica. He has an equity interest in A-Trantion. Drs. Shiraishi, Nishizawa, Yamamoto, Tsukada, and Sasaki have no conflicts of interest or financial ties to disclose.
The study was approved by the institutional review board.
For this type of study formal consent is not required.